Mr. Grover received his B.A. degree, cum laude , from Harvard College in 1980 and his J.D. degree from the University of Virginia School of Law in 1985. Mr. Grover joined the San Francisco office of Morrison & Foerster in 1985, became a partner in 1992. Mr. Grover has held various management positions including Co-Head of the firm’s interdisciplinary Life Sciences Group and Co-Head of the firm’s Public Companies and Corporate Groups for nine years. He presided over the rapid expansion of the Corporate Group from 65 lawyers when he became Co-Head in 1996 to more than 200 lawyers today. He currently serves as a co-chair of the firmwide Mergers & Acquisitions Group.

Mr. Grover’s practice has been primarily oriented towards representation of emerging growth companies in a wide variety of transactional matters. Mr. Grover serves as corporate secretary and primary outside counsel to a large number of both private and public emerging growth companies and counsels companies from formation through the initial public offering stage and beyond to ultimate sale or merger. Mr. Grover has been involved in over 250 merger and acquisition, financing and strategic alliance matters at Morrison & Foerster. He has completed a large number of mergers and acquisition transactions for both public and private companies including tender offers, auctions, special committee representations and customary negotiated acquisition structures including: representation of VISX, Incorporated in its merger with Advanced Medical Optics, Inc. to create a $3 billion market capitalization company in the optical care market. Several of Mr. Grover’s recent transactions include representing Verio, Inc. in the acquisition of approximately 40 Internet companies, including Hiway Technologies, Inc., as well as its initial public offering, more than $700 million of high-yield financing, and numerous strategic relationships; the Board of Directors of VISX, Incorporated , in its $1.3 billion sale to Advanced Medical Optics, Inc.; Verio, Inc. in its $6 billion dollar sale to NTT; PMC-Sierra, Inc. in its sale to Sierra Semiconductor Corporation; Nellcor Incorporated in its $600 million stock for stock merger with Puritan-Bennett Corporation; Creative Technology Ltd. in its acquisition of 3Dlabs Inc., Ltd.; Digimarc Corporation in its acquisition of the Polaroid ID Systems business; and Davide Campari - Milano S.p.A. in its purchase of a majority interest in Skyy Spirits, LLC.

During the last several years, Mr. Grover has also handled a number of strategic alliance and joint venture transactions which are an increasingly common alternative to traditional acquisitions. Several of Mr. Grover’s recent transactions include representing: (i)  SmithKline Beecham plc in the formation with Incyte Pharmaceuticals, Inc. of diaDexus LLC, a joint venture using genomics to develop diagnostic products; (ii)  Angeion Corporation in its worldwide alliance with Synthélabo for implantable cardioverter defibrillators and related cardiac stimulation devices; (iii)  Progenitor, Inc. in its strategic relationship with Amgen Inc. concerning the leptin receptor; and (iv)  GlaxoSmithKline in its divestiture of a partial interest in Affymax; and (v) Verio, Inc. in its $100 million financing and strategic relationship with Nippon Telegraph & Telephone.

Mr. Grover has also represented numerous companies, underwriters, and intermediaries in a wide range of financings and restructurings, including a variety of initial public offerings, Rule 144A and other private offerings, debt placements, subordinated and high-yield debt financings, PIPEs, “registered directs,” medium-term-note programs, problem loan work-outs and recapitalizations including numerous financings from initial public offerings to PIPEs and “registered directs” by public companies such as Xenogen Corporation; Nanogen Inc.; TMNG; Pivotal Corporation; Internap; Sigmatel, Inc.; Angeion Corporation; Restoration Hardware; Digimarc Corporation; Verio, Inc.; Finisar Corporation and Progenitor, Inc.

Mr. Grover is the author of numerous articles in the securities field including Disclosure Requirements for Legal Proceedings Under Federal Securities Laws , Boardroom “Best” Practices are Changing: The Need to Demonstrate “Good Faith,” Sarbanes-Oxley “Hotline” Procedures: Who Should be Doing the Listening? and Checklist of Key Issues in Renewing D&O Liability Insurance, and publications concerning Sarbanes-Oxley compliance requirements. Mr. Grover is also active in a number of business and professional groups.